Development of inclusion complex based on cyclodextrin and oxazolidine derivative

Oxazolidine derivatives (OxD) have been described as third-line antibiotics and antitumoral agents. The inclusion complexes based on cyclodextrin could improve the solubility bioavailability of these compounds. A novel synthetic OxD was used, its were 2-hydroxy-beta-cyclodextrin (2-HPβCD). We conducted an in silico study to evaluate interaction capacity between 2-HPβCD. Characterization studies performed through scanning electron microscopy (SEM), Fourier-transformed infrared (FTIR), nuclear magnetic resonance spectroscopy (1H-NMR), X-ray diffraction (XRD), thermal analyses. kinetic performed, including a cytotoxicity assay using peripheral blood mononuclear cells (PBMCs). maximum increment obtained at 70 mM 400 SEM analyses FTIR spectra indicated formation complexes. 1H-NMR presented chemical shifts that 1:1 stoichiometry. Different behaviors obtained. pharmacokinetic profile showed short release time. Pure complex did not exhibit PBMCs. In provided foremost insight into interactions 2-HPβCD, higher water average releasing without toxicity normal cells.